NantHealth (NASDAQ:NH) Earns Hold Rating from Analysts at

Equities research analysts at started coverage on shares of NantHealth (NASDAQ:NHGet Rating) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the stock.

NantHealth Stock Performance

Shares of NH opened at $0.28 on Monday. The company has a 50-day simple moving average of $0.33 and a 200-day simple moving average of $0.46. The firm has a market capitalization of $32.37 million, a P/E ratio of -0.55 and a beta of 2.06. NantHealth has a 52 week low of $0.17 and a 52 week high of $1.50.

NantHealth (NASDAQ:NHGet Rating) last announced its quarterly earnings data on Thursday, November 3rd. The company reported ($0.13) EPS for the quarter. The firm had revenue of $16.63 million for the quarter. As a group, equities analysts forecast that NantHealth will post -0.39 earnings per share for the current year.

Institutional Trading of NantHealth

Several hedge funds have recently modified their holdings of NH. Highbridge Capital Management LLC acquired a new position in NantHealth in the first quarter valued at approximately $665,000. Atria Wealth Solutions Inc. raised its holdings in shares of NantHealth by 117.7% during the second quarter. Atria Wealth Solutions Inc. now owns 491,942 shares of the company’s stock worth $205,000 after acquiring an additional 265,949 shares during the period. Millennium Management LLC acquired a new stake in shares of NantHealth during the second quarter worth $110,000. Goldman Sachs Group Inc. acquired a new stake in shares of NantHealth during the second quarter worth $36,000. Finally, Hartline Investment Corp acquired a new stake in shares of NantHealth during the second quarter worth $65,000. 4.67% of the stock is owned by institutional investors.

NantHealth Company Profile

(Get Rating)

NantHealth, Inc, together with its subsidiaries, operates as a healthcare IT company in the United States, Canada, and the United Kingdom. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions.

Further Reading

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with's FREE daily email newsletter.